Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Positive Outlook on Cohen Steers with Increased Price Target

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Finance_Capitalization
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

On March 8, 2024, analyst John Dunn from Evercore ISI Group reaffirmed his positive outlook on Cohen & Steers (NYSE:CNS), giving it an Outperform rating. He also increased the price target for the stock from $77 to $78. Looking ahead, the average stock forecast for Cohen & Steers Inc (CNS) over the next year is $75.48 USD, suggesting a potential upside of 7.83%.

CNS Stock Shows Strong Performance on March 8, 2024: Positive Sign for Investors

On March 8, 2024, CNS stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. According to data from CNN Money, the price of CNS shares increased by $0.99 since the market last closed, representing a 1.31% rise.

The stock opened at $76.27, which was $0.51 higher than its previous close. This positive price momentum indicates that investors have confidence in the company and its future prospects.

CNS’s strong performance on March 8th may be attributed to a variety of factors, such as positive earnings reports, new product launches, or overall market trends. Investors may be optimistic about the company’s growth potential and are willing to buy shares at a higher price.

It is important to note that stock prices can be volatile and subject to market fluctuations. While CNS had a positive trading day on March 8th, there is no guarantee that this momentum will continue in the future.

Investors should conduct thorough research and consider their own risk tolerance before making investment decisions. Consulting with a financial advisor can also provide valuable insights and guidance on navigating the stock market.

Overall, CNS’s strong performance on March 8, 2024, is a positive sign for the company and its shareholders. With continued momentum and favorable market conditions, CNS may continue to see growth and success in the future.

CNS Stock Performance Declines in 2024: Revenue and Net Income Drop, EPS Decreases

On March 8, 2024, CNS stock performance was closely watched by investors as the company released its financial results for the past year and the fourth quarter. According to data from CNN Money, CNS reported a total revenue of $483.62 million for the past year, which was a decrease of 15.75% compared to the previous year. The total revenue for the fourth quarter was $116.86 million, which remained flat compared to the previous quarter.

In terms of net income, CNS reported a net income of $129.05 million for the past year, which was a decrease of 24.55% compared to the previous year. The net income for the fourth quarter was $29.82 million, which also remained flat compared to the previous quarter.

Earnings per share (EPS) for CNS were reported at $2.60 for the past year, which was a decrease of 24.94% compared to the previous year. The EPS for the fourth quarter was $0.60, which was a decrease of 7.44% compared to the previous quarter.

Overall, the financial results for CNS showed a decline in both total revenue and net income compared to the previous year. However, the company was able to maintain its revenue and income levels from the previous quarter. The decrease in EPS indicates that the company’s profitability has been impacted by various factors.

Investors and analysts will be closely monitoring CNS stock performance in the coming days to see how the market reacts to these financial results. It will be interesting to see how CNS plans to address the challenges it is facing and whether it can turn its performance around in the future.

Tags: CNS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ Chart up

Analyst Reaffirms Positive Outlook on Duckhorn Portfolio with Adjusted Price Target

Finance_ Chart Down

Analyst Reaffirms Positive Outlook on Federated Hermes with Increased Price Target

Real Estate Investment Trading online

Safe and Green Development Corp Expands Norman Berry Property for Senior Living Facility

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com